Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials

The combination of EGFR inhibitors and anti-angiogenic drugs has a strong pre-clinical rationale, yet its use has produced controversial clinical results. We conducted two sequential phase I trials to evaluate the feasibility and the recommended dose of erlotinib when combined with fluoropyrimidine-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: CARLOMAGNO, CHIARA, DANIELE, GENNARO, BIANCO, ROBERTO, MARCIANO, ROBERTA, DAMIANO, VINCENZO, MATANO, ELIDE, NAPPI, LUCIA, PEPE, STEFANO, DE PLACIDO, SABINO, TORTORA, GIAMPAOLO
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2011
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3440709/
https://ncbi.nlm.nih.gov/pubmed/22977524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2011.218
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados